Department of Urology, University of Washington School of Medicine, Seattle, Washington; Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Prostate. 2014 Jan;74(1):97-102. doi: 10.1002/pros.22733. Epub 2013 Sep 21.
Digoxin is a commonly used medication for heart failure and cardiac arrhythmias that has recently been suggested as a novel chemotherapeutic agent. Preclinical studies of prostate cancer (PCa) have shown anti-tumor activity with digoxin. We explore the relationship between use of digoxin and PCa risk.
Data from a population-based case-control study of incident cases aged 35-74 years at PCa diagnosis in 2002-2005 in King County, Washington were available. Controls were identified by random digit dialing and frequency matched by age. Use of digoxin was determined from in-person questionnaires regarding medical and prescription history. The relationship of digoxin use with PCa risk was evaluated with logistic regression.
One thousand one cases of PCa and 942 controls were analyzed. The prevalence of digoxin use in controls was 2.7%, and use was positively correlated with age. In multivariate analysis adjusting for age, race, PSA screening, and family history of PCa, digoxin use was associated with a reduction in the odds ratio of PCa (OR 0.58, 95% CI: 0.30-1.10). Among those with ≥3 PSA tests over the preceding 5 years (546 cases, 380 controls), digoxin use was associated with a stronger reduction of PCa risk (OR 0.44, 95% CI: 0.20-0.98).
These data indicate digoxin use may be associated with a reduction in risk of PCa. Given the potential mechanisms by which digoxin may exert an anti-neoplastic effect and other recent studies showing a negative association between digoxin use and PCa, further research is warranted.
地高辛是一种常用于心力衰竭和心律失常的药物，最近有研究表明它也是一种新型化疗药物。前列腺癌（PCa）的临床前研究表明地高辛具有抗肿瘤活性。我们探讨了地高辛的使用与 PCa 风险之间的关系。
本研究的数据来自于 2002-2005 年在华盛顿州金县诊断为 PCa 的年龄在 35-74 岁的病例对照研究。对照组通过随机数字拨号确定，并按年龄匹配频率。通过面对面问卷了解有关医疗和处方史的情况，确定地高辛的使用情况。使用逻辑回归评估地高辛使用与 PCa 风险的关系。
共分析了 1100 例 PCa 病例和 942 例对照。对照组中地高辛的使用率为 2.7%，且使用与年龄呈正相关。在调整年龄、种族、PSA 筛查和 PCa 家族史等因素的多变量分析中，地高辛的使用与 PCa 风险的比值比降低相关（OR 0.58，95%CI：0.30-1.10）。在过去 5 年内进行了≥3 次 PSA 检测的人群中（546 例病例，380 例对照），地高辛的使用与 PCa 风险的降低更显著（OR 0.44，95%CI：0.20-0.98）。
这些数据表明，地高辛的使用可能与 PCa 风险降低有关。鉴于地高辛可能发挥抗肿瘤作用的潜在机制，以及最近其他研究表明地高辛的使用与 PCa 之间呈负相关，因此需要进一步研究。
